The decision comes after medical advisors decided that Johnson & Johnson s single-dose Covid-19 vaccine’s benefits outweigh the risk of recipients developing a blood clot.
U.S. health officials lifted an 11-day pause on COVID-19 vaccinations using Johnson & Johnson s single-dose shot on Friday, after scientific advisers decided its benefits outweigh a rare risk of blood
U.S. to resume Johnson & Johnson vaccinations despite rare clot risk
Scientific advisers said the benefits of the one-dose coronavirus vaccine outweigh the rare risk of blood clots..
Â
Â
In this March 26 photo, a member of the Philadelphia Fire Department prepares a dose of the Johnson & Johnson COVID-19 vaccine at a vaccination site setup at a Salvation Army location in Philadelphia. [ MATT ROURKE | AP ]
Updated 52 minutes ago
U.S. health officials lifted an 11-day pause on COVID-19 vaccinations using Johnson & Johnsonâs single-dose shot on Friday, after scientific advisers decided its benefits outweigh a rare risk of blood clot.
The government uncovered 15 vaccine recipients who developed a highly unusual kind of blood clot out of nearly 8 million people given the J&J shot. All were women, most under age 50. Three died, and seven remain hospitalized.
Scientific advisers decided its benefits outweigh the rare risk of adverse side effects.
The government uncovered 15 vaccine recipients who developed a highly unusual kind of blood clot, out of nearly eight million people given the J&J jab.
All were women, most under 50, and three died while seven remain in hospital.
The Food and Drug Administration and Centres for Disease Control and Prevention (CDC) decided that J&J’s one-and-done vaccine is critical to fight the pandemic – and that the small clot risk could be handled with warnings to help younger women decide if they should use that shot or an alternative.
US lifts pause, allowing Johnson & Johnson COVID-19 vaccinations to resume
Lauran Neergaard and Mike Stobbe, Associated Press
Share This
EastIdahoNews.com file photo
U.S. health officials lifted an 11-day pause on COVID-19 vaccinations using Johnson & Johnson’s single-dose shot on Friday, after scientific advisers decided its benefits outweigh a rare risk of blood clot.
The government uncovered 15 vaccine recipients who developed a highly unusual kind of blood clot, out of nearly 8 million people given the J&J shot. All were women, most under age 50. Three died, and seven remain hospitalized.
But ultimately Friday, the Food and Drug Administration and Centers for Disease Control and Prevention decided that J&J’s one-and-done vaccine is critical to fight the pandemic and that the small clot risk could be handled with warnings to help younger women decide if they should use that shot or an alternative.